XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE, Calif.
| Revenue (Most Recent Fiscal Year) | $52.15M |
| Net Income (Most Recent Fiscal Year) | $31.71M |
| PE Ratio (Current Year Earnings Estimate) | 42.24 |
| PE Ratio (Trailing 12 Months) | 128.10 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 9.07 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.86 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 69.65 |
| Pre-Tax Margin (Trailing 12 Months) | 61.01% |
| Net Margin (Trailing 12 Months) | 45.75% |
| Return on Equity (Trailing 12 Months) | 10.32% |
| Return on Assets (Trailing 12 Months) | 3.49% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.37 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.15 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.77 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.12 |
| Earnings per Share (Most Recent Fiscal Year) | $0.66 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.46 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 11.92M |
| Free Float | 10.86M |
| Market Capitalization | $473.17M |
| Average Volume (Last 20 Days) | 0.14M |
| Beta (Past 60 Months) | 0.68 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |